Provided by Healio
October 21, 2013
SAN DIEGO — Christophe Moreno, MD,PhD, reports that treatment-naive patients with chronic hepatitis C genotype 1 infection showed significantly increased sustained virological response 12 weeks after planned end of treatment when treated with faldaprevir plus pegylated interferon alfa-2a and ribavirin compared with peginterferon and ribavirin alone.
Moreno, director of the gastroenterology department at Erasme Hospital, Brussels, discusses the final results of STARTVerso1, a randomized, double blind, placebo-controlled, phase 3 trial at the American College of Gastroenterology Annual Scientific Meeting.
Disclosure: Moreno is a board member with Janssen, Gilead, MSD and Bristol-Myers Squibb, received grants from Janssen, Roche and Novartis and is a member of the speakers bureau with MSD, Janssen and Bristol-Myers Sqibb.